Evaluation and management of hypertension in Spain. A consensus guide;Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso

Medicina Clinica

Volumn 131, Issue 3, 2008, Pages 104-118

  De La Sierra, Alejandro ^a   Gorostidi, Manuel ^a   Marín, Rafael ^a   Redón, Josep ^a   Banegas, José R ^a   Armario, Pedro ^a   Puig, Juan García ^a   Zarco, Julio ^a   Llisterri, José L ^a   Sanchís, Carlos ^a   Abarca, Benjamín ^a   Palomo, Vicente ^a   Gomis, Ramón ^a   Otero, Alfonso ^a,b   Villar, Fernando ^a   Honorato, Jesús ^b   Tamargo, Juan ^b   Lobos, José M ^c   Macías Núñez, Juan ^a   Sarría, Antonio ^d   Arand, Pedro ^a   Ruilopea, Luis M ^a   more..

^a Sociedad Española de Medicina Interna ^*

^b Sociedad Española de Farmacología Clínica

^c Sociedad Española de Nefrología ^*

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

ARTERIAL PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CEREBROVASCULAR DISEASE; CLINICAL EVALUATION; CONFERENCE PAPER; CONSENSUS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; PREVALENCE; PROGNOSIS; PROPHYLAXIS; SCORING SYSTEM; SPAIN; SYSTOLIC BLOOD PRESSURE;

EID: 46449130024     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13124015     Document Type: Conference Paper

References (117)

1. Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-87.
3. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial. Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2002. Hipertensión. 2002;19 Supl 3:1-74.
4. Marín R, Armario P, Banegas JR, Campo C, De la Sierra A, Gorostidi M. Guía Española de Hipertensión Arterial 2005. Hipertensión. 2005;22 Supl 2:1-84.
5. Marín R, De la Sierra A, Armario P, Campo C, Banegas JR, Gorostidi M. Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2005. Med Clin (Barc). 2005;125:24-34.
6. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
7. Pastor R, Banegas JR, Damián J, Appel LJ, Guallar E. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med. 2003;139:731-9.
8. De la Sierra A. Valor de la presión de pulso como marcador de riesgo cardiovascular. Med Clin (Barc). 2006;126:384-8.
9. Banegas JR, Rodríguez Artalejo F, Cruz JJ, Guallar P, Rey J. Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension. 1998;32:998-1002.
10. Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, Cruz JJ, et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens. 2002;20:2157-64.
11. Banegas JR, Rodríguez Artalejo F, Cruz JJ, De Andrés B, Rey J. Mortalidad relacionada con la presión arterial y la hipertensión en España. Med Clin (Barc). 1999;112:489-94.
12. Villar F, Banegas JR, Donado JM, Rodríguez Artalejo F. Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe SEA 2007. Madrid: SEA; 2007.
13. Banegas JR, Segura J, Ruilope LM, Luque M, García-Robles R, Campo C, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension. 2004; 43:1338-44.
14. Banegas JR, Segura J, Sobrino J, Rodríguez-Artalejo F, De la Sierra A, De la Cruz JJ, et al, for the Spanish Society of Effectiveness of blood pressure control outside the medical setting. Hypertension. 2007; 49:62-8.
15. Llisterri JL, Rodríguez GC, Alonso F, Banegas JR, González-Segura D, Lou S, et al. Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2006. Med Clin (Barc). 2008;130:681-7
16. D'Agostino RBS, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-7.
17. Marrugat J, Subirana I, Comin E, Cabezas C, Vila J, Elosua R, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007;61:40-7.
18. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
19. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al, on behalf of the Fourth Joint Task Force of the European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007; 28:2375-414.
20. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professionals and Public Education of The American Heart Association Council on High Blood Pressure Research. Hypert
21. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al; on behalf of the European Society of Hypertension Work Practice guidelines of the European Society of Hypertension. Clinical, ambulatory and self blood pressure measurement. J Hypertens. 2005;23:697-701.
22. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, et al. Home blood pressure measurement has a stronger predictive power for mortality that does screening blood pressure: a population-based observation in Ohasama, Japan. J Hypertens. 1998;16:971-7.
23. British Hypertension Society [consultado 17/09/2007]. Disponible en: www.bhsoc.org/blood_pressure_list.stm
24. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821-48.
25. Martínez MA, Sancho T, García P, Moreno P, Rubio JM, Palau FJ, et al. Home blood pressure in poorly controlled hypertension: relationship with ambulatory blood pressure and organ damage. Blood Press Monit. 2006;11:207-13.
26. Vinyoles E, Felip A, Pujol E, De la Sierra A, Durán R, Hernández del Rey R, et al, on behalf of the Spanish Society of H Clinical characteristics of isolated clinic hypertension. J Hypertens. 2008;26:438-45.
27. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation. 1998;98:1892-7.
28. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203-8.
29. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of «masked» hypertension and «white-coat» hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508-15.
30. Lurbe E, Torro I, Álvarez V, Nawrot T, Paya R, Redon J, et al. Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension. 2005;45:493-8.
31. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognosis significance of the nocturnal decline in blood pressure in individuals with and without high 24 h blood pressure: the Ohasama study. J Hypertens. 2002;20:2183-9.
32. Gorostidi M, Sobrino J, Segura J, Sierra C, De la Sierra A, Hernández del Rey R, et al, on behalf of the Spanish Society Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20 000-patient database in Spain. J Hypertens. 2007;25:977-84.
33. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712-8.
34. Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2008;51:69-76.
35. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis. 2004;44:84-93.
36. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
37. Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology a
38. The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
39. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Human Hypertens. 2004;18:139-85.
40. Egocheaga MI, Lobos JM, Álvarez-Guisasola F, Alcázar R, Orte L, González-Parra E, et al. Documento de consenso sobre la enfermedad renal crónica. Sociedad Española de Nefrología (SEN) y Sociedad Española de Medicina de Familia y Comunitaria (semFYC) [consultado 20/02/2008]. Disponible en: www.senefro.org
41. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-7.
42. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.
43. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-53.
44. Peterson JC, Adler A, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-62.
45. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al, for the Blood Pressure Lowering Treatment Trialist Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-9.
46. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40.
47. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-38.
48. Staessen JA, Gasowski J, Wang JG, Thijs L, Hond ED, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-72.
49. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;355:1955-64.
50. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressurelowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.
51. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-6.
52. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomised, double-blind, long-term trial. Circulation. 2002;106:2422-7.
53. Sierra C, De la Sierra A. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol Hypertens. 2005;14:435-41.
54. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al, the National High Blood Pressure Educations Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JNC 7 - Complete version. Hypertension. 2003;42:1206-52.
55. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-76.
56. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368: 1449-56.
57. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de medicamentos 2007. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2007. p. 811-1007.
58. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999;353:2008-13.
59. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003;24:1601-10.
60. Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC), Brotons C, Royo-Bordonada MA, Álvarez-Sala Adaptación española de la Guía Europea de Prevención Cardiovascular. Aten Primaria. 2004;34:427-32.
61. U.S S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157-60.
62. Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med. 2002;346:1468-74.
63. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al, for the ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet. 2003;361:1149-58.
64. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
65. Yánez-Cadena D, Sarría-Santamera A, García-Lizana F. ¿Podemos mejorar el tratamiento y el control de las enfermedades crónicas? Aten Primaria. 2006;37:221-30.
66. SHEP Collaborative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-64.
67. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al, for the Systolic Hypertension in Europe (Sy Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-64.
68. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA. 2002;288:1491-8.
69. Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Ololfsson B, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44:1175-80.
70. Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, et al, on behalf of the Hipertensión in the V Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003;21:2409-17.
71. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrescu D, et al. Treament of hypertension in patients 80 years of age or older. N Engl J Med. 2008;Mar 31 [Epub ahead of print].
72. American Diabetes Association. Executive summary: standards of medical care in diabetes 2008. Diabetes Care. 2008;31 Suppl 1:5-11.
73. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Álvarez V, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797-805.
74. Astrup AS, Nielsen FS, Rossing P, Ali S, Kastrup J, Smidt UM, et al. Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens. 2007;25:2479-85.
75. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.
76. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al, Bergamo Nephrologic Diabetes Complications Trial Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-51.
77. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet. 2007;369:201-7.
78. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al, for the Trial of Preventing Hypertension (TROP Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-97.
79. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. The Task Force on betablockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25:1341-62.
80. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al, for the INVEST Invetigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-16.
81. Poole-Wilson PA, Lubsen J, Kirwan BA, Van Dalen FJ, Wagener G, Danchin N, et al, on behalf of the ACTION (A Coronary dis Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet. 2004;364:849-57.
82. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al, for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-26.
83. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al, on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-77.
84. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortalilty and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342:821-8.
85. Pfeffer MA, McMurray JJV, Velázquez EJ, Rouleau JL, Køber L, Maggioni AP, et al, for the Valsartan in Acute Myocardial I Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349;1893-906.
86. Fox KM. Efficacy on perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet. 2003;362:782-8.
87. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-68.
88. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.
89. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J. 2005;26:1115-40.
90. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25.
91. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A, et al, for The Randomized Aldactone Evaluation Study Investiga The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17.
92. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543-51.
93. Pitt B, Poole-Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-7.
94. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
95. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al, for the CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet. 2003;362:759-66.
96. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al, for the CHARM Investigators and Committee Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet. 2003;362:767-71.
97. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet. 2003;362:772-6.
98. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM Preserved Trial. Lancet. 2003;362: 777-81.
99. Redón J, Cea-Calvo L, Lozano JV, Martí-Canales JC, Llisterri JL, Aznar J, et al; PREV-ICTUS Study. Differences in blood pressure control and stroke mortality across Spain: the Prevención de Riesgo de Ictus (PREV-ICTUS) study. Hypertension. 2007;49:799-805.
100. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359: 995-1003.
101. Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Papademetriou V, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE) - major cardiovascular events and stroke in subgroups of patients. Blood Press. 2005;14:31-7.
102. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al, MOSES Study Group. Morbidity and mortality after stroke. Eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-26.
103. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-69.
104. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
105. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al, for the National Kidney Foundation Hypertension Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646-61.
106. Ruilope L, Kjeldsen SE, De la Sierra A, Mancia G, Ruggenenti P, Stergiou GS (with the collaboration of Bakris GL & Giles The kidney and cardiovascular risk - Implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007; 16:72-9.
107. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, De Jong PE, et al, for the AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med. 2003;139:244-52.
108. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43 Suppl 1:1-290.
109. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet. 2003;361:117-24.
110. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16: 3038-45.
111. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:1921-6.
112. Marín R, Fernández-Vega F, Gorostidi M, Ruilope LM, Díez J, Praga M, et al, on behalf of the COPARENAL (COntrol de la hi Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. J Hypertens. 2006;24:395-402.
113. Marín R, Goicoechea M, Gorostidi M, Cases A, Díez J, Escolar G, et al, en representación del Comité de Expertos de la Gu Riñón y enfermedad vascular. Guía de la Sociedad Española de Nefrología sobre riñón y enfermedad vascular. Versión abreviada. Nefrología. 2006;26:31-44.
114. Aguilera MT, De la Sierra A, Coca A, Estruch R, Fernández- Solá J, Urbano-Márquez A. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension. 1999;33:653-7.
115. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271-7.
116. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007;25:891-4.
117. López AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-57.